Federal Circuit's Patent Ruling Could Broadly Affect Biotech

A ruling last Friday by a three-judge panel from the U.S. Court of Appeals for the Federal Circuit, which affirmed the government's rejection of a patent application filed by two Amgen Inc. scientists, could not only impede gene patenting, but could make all medical-related patents more difficult to obtain. (BioWorld Today)